Acurx Pharmaceuticals’ (ACXP) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Acurx Pharmaceuticals (NASDAQ:ACXP) in a research report released on Thursday,Benzinga reports. They currently have a $12.00 price objective on the stock.

Acurx Pharmaceuticals Stock Performance

ACXP traded down $0.09 during trading on Thursday, reaching $1.68. The company had a trading volume of 22,556 shares, compared to its average volume of 89,944. The business’s fifty day moving average price is $1.96 and its 200 day moving average price is $2.14. Acurx Pharmaceuticals has a 12 month low of $1.52 and a 12 month high of $5.28.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its earnings results on Tuesday, November 12th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. During the same quarter last year, the business earned ($0.24) earnings per share. On average, analysts forecast that Acurx Pharmaceuticals will post -0.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Acurx Pharmaceuticals

An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC lifted its position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 1.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 278,100 shares of the company’s stock after buying an additional 5,250 shares during the quarter. Prospect Financial Services LLC owned about 1.76% of Acurx Pharmaceuticals worth $626,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.